capmatinib hydrochloride

capmatinib hydrochloride (TABRECTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

TABRECTA is a marketed brand name for capmatinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

capmatinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.